BACKGROUND: The study stemmed from an incidental observation of improvement in 2 @entity1 with @entity17393 while receiving @entity2929 . OBJECTIVE: The purpose of the study was to evaluate the efficacy of @entity2929 in @entity1 with @entity17393 . METHODS: A double-blind, placebo-controlled clinical study was performed in an outpatient setting in a major hospital. Ninety @entity1 over a period of 2 years were alternatively assigned to treatment group or placebo group. @entity1 in the treatment group received @entity2929 in divided doses for 14 days. The response was categorized as complete response, partial response, or no response. All @entity1 were followed up for 6 weeks. RESULTS: Both groups were comparable with regard to age at presentation, sex, and average duration of disease at the time of reporting to the clinic. Upper @entity1729 before the appearance of @entity272 was reported in 68.8% of all @entity1 . Complete response was observed in 33 @entity1 (73.33%) in the treatment group and none in the placebo group (P <.0001). CONCLUSION: Oral @entity2929 was effective in treating @entity1 with @entity17393 .

XXXX in @entity17393 : A double-blind, placebo-controlled clinical trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2929 :: ('MESH:D004917', 'Chemical') :: ['erythromycin'] @entity17393 :: ('MESH:D017515', 'Disease') :: ['pityriasis rosea'] @entity1729 :: ('MESH:D012141', 'Disease') :: ['respiratory tract infection'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin lesions']
@entity2929 :: (MESH:D004917,Chemical) :: ['Erythromycin']
